References
- Imai S, Armstrong C M, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795–800
- Voelter-Mahlknecht S, Mahlknecht U. Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med 2006; 17: 59–67
- Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417–435
- Brunet A, Sweeney L B, Sturgill J F, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011–2015
- Cohen H Y, Lavu S, Bitterman K J, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627–638
- Luo J, Nikolaev A Y, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137–148
- Vaziri H, Dessain S K, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149–159
- Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007; 299: 103–106
- Huffman D M, Grizzle W E, Bamman M M, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612–6618
- Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 2005; 102: 1859–1864
- Lim C S. SIRT1: tumor promoter or tumor suppressor?. Med Hypotheses 2006; 67: 341–344
- Baylin S B, Ohm J E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006; 6: 107–116
- Lim C S. Human SIRT1: a potential biomarker for tumorigenesis?. Cell Biol Int 2007; 31: 636–637
- Chen W Y, Wang D H, Yen R C, Luo J, Gu W, Baylin S B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437–448
- Hogg R, Scurry J, Kim S N, Friedlander M, Hacker N. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 2007; 106: 44–51
- Ozdag H, Teschendorff A E, Ahmed A A, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006; 7: 90
- Yeung F, Hoberg J E, Ramsey C S, et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J 2004; 23: 2369–2380
- Shahin M S, Hughes J H, Sood A K, Buller R E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006–2017
- Wen W H, Reles A, Runnebaum I B, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999; 18: 29–41
- Geisler J P, Geisler H E, Wiemann M C, Givens S S, Zhou Z, Miller G A. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435–438
- Klemi P J, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201–1208